Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ITI-007 for Agitation in Dementia
NCT02817906Phase 3Terminated
- Sponsor
- Intra-Cellular Therapies
- Start
- Aug 2016
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in agitation comparing ITI-007 with Placebo (2 arms). Primary endpoint: Cohen-Mansfield Agitation Inventory - Community Version at 4 weeks. Started Aug 2016; status: terminated.
02
Drugs
lumateperone
03
Conditions
agitation
Beyond the preview
Go deeper on NCT02817906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02817906.